Newmont's (NEM) Q1 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2262672/newmont-s-nem-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2262672
Apr 25, 2024 - Newmont's (NEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.
0
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
https://www.zacks.com/stock/news/2262625/revvity-s-rvty-new-launch-to-boost-tuberculosis-testing?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2262625
Apr 25, 2024 - Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
0
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
https://www.zacks.com/stock/news/2261445/penumbra-s-pen-new-launch-to-enhance-blood-clot-removal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2261445
Apr 24, 2024 - Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
0